Treatments of choice for bullous pemphigoid.

Journal article

Bullous pemphigoid (BP) is the most frequently occurring autoimmune blistering disease in Europe and North America. Although it is primarily a disease of the elderly, children and young adults can also develop it. The aim of treatment is to suppress the clinical signs and symptoms of BP without over-treating the patient, because BP tends to spontaneously remit in most patients within approximately 5 years. Mild or localized disease may respond to super-potent topical corticosteroids alone or in combination with tetracyclines with or without niacinamide. More severe or generalized disease usually requires systemic treatment with prednisolone (dose range from 20-70 mg/d). Additional immunosuppressant therapy is necessary for more refractory disease.

Authors: Cooper, S; Wojnarowska, F

• Journal: Skin therapy letter
• Volume: 7
• Issue: 1
• Pages: 4-6
• Publication date: 2002-01-01
• ISSN: 1201-5989
• Language: English
• Keywords: Humans; Pemphigoid, Bullous